Mangoceuticals MGRX Income Statement (2022-2026)

NASDAQ MGRX
$0.41 +0.02 (+5.13%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

Mangoceuticals Quarterly Income Statement

Periods 15 quarters
Latest Jun 2026

Mangoceuticals reported revenue of $0.07M and net income of -$1.31M for the quarter ended Jun 2026, down 59.1% year over year. This income statement covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue 0.10M0.14M0.25M0.24M0.21M0.16M0.13M0.11M0.11M0.17M0.08M0.09M0.07M0.07M
Cost of RevenueCost of Rev 0.02M0.03M0.05M0.05M0.02M0.03M0.02M0.02M0.02M0.02M0.00M0.01M0.01M0.01M
Gross Profit 0.06M0.09M0.14M0.14M0.15M0.07M0.08M0.08M0.06M0.09M0.05M0.05M0.03M0.04M
Operating items
Amortization - Intangibles 0.28M0.28M
Selling, General & AdministrativeSG&A 0.13M0.57M0.54M0.82M0.77M0.85M0.52M0.85M1.54M1.25M0.31M0.66M1.05M0.26M
Other Operating ExpensesOther Opex 2.49M1.81M1.40M1.89M1.74M1.39M1.32M0.90M3.10M4.11M7.28M-0.24M2.10M0.82M
Operating ExpensesOpex 2.62M2.38M1.94M2.71M2.52M2.24M1.84M1.76M4.64M5.36M7.59M0.42M3.16M1.08M
Operating IncomeOp. Inc -2.56M-2.29M-1.80M-2.57M-2.37M-2.17M-1.76M-1.68M-4.58M-5.27M-7.54M-0.37M-3.13M-1.03M
EBIT -2.56M-2.29M-1.80M-2.57M-2.37M-2.17M-1.76M-1.68M-4.58M-5.27M-7.54M-0.37M-3.13M-1.03M
Non-operating items
Non Operating Interest Expenses -0.01M0.02M0.08M0.02M
Other Non Operating IncomeOther Non Op Inc. -0.13M0.11M
Non Operating IncomeNon Op. Inc. -0.00M0.01M-0.22M-0.24M-0.27M-0.26M-0.15M-0.08M-2.40M-0.28M-0.28M
Net income details
EBT -2.56M-2.28M-1.80M-2.57M-2.37M-2.39M-2.00M-1.95M-4.84M-5.42M-7.62M-2.77M-3.40M-1.31M
Profit After TaxPAT -2.56M-2.28M-1.80M-2.57M-2.37M-2.39M-2.00M-1.95M-4.84M-5.42M-7.62M-2.77M-3.40M-1.31M
Income from Non-Controlling InterestsInc. Minority -1.80M-36.00-340.00-461.00-244.00-98.00-2.00-558.00197.00-0.00M-278.00
Income from Continuing OperationsIncome (Continuing) -2.56M-2.28M-1.80M-2.57M-2.37M-2.39M-2.00M-1.95M-4.84M-5.42M-7.62M-2.77M-3.40M-1.31M
Consolidated Net IncomeConsol Net Inc. -2.56M-2.28M-1.80M-2.57M-2.37M-2.39M-2.00M-1.95M-4.84M-5.42M-7.62M-2.77M-3.40M-1.31M
Income towards Parent CompanyParent Net Inc -2.56M-2.28M-1.80M-2.57M-2.37M-2.39M-2.00M-1.95M-4.84M-5.42M-7.62M-2.77M-3.40M-1.31M
Preferred Dividend PaymentsPref Dividends 0.29M0.29M0.29M0.29M0.29M0.29M0.29M
Net Income towards Common StockholdersNet Income -2.56M-2.28M-1.80M-2.57M-2.37M-2.39M-2.29M-1.95M-5.13M-5.71M-7.91M-3.06M-3.70M-1.61M
Additional items
EPS (Basic) -3.41-2.17-1.70-2.39-1.56-1.37-1.14-0.98-1.12-0.57-0.69-0.30-0.22-0.09
EPS (Diluted) -3.41-2.17-1.70-2.39-1.56-1.37-1.14-0.98-1.12-0.57-0.69-0.30-0.22-0.09
Shares Outstanding 0.72M0.75M1.05M1.06M1.07M1.52M1.74M2.01M1.98M4.59M9.98M11.52M10.07M16.48M17.12M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 0.72M0.75M1.05M1.06M1.07M1.52M1.74M2.01M1.98M4.59M9.98M11.52M10.07M16.48M17.12M
Shares Outstanding (Entity)Shares Outstanding (Entity.) 0.72M0.75M1.11M1.12M1.07M1.57M1.94M2.13M1.98M4.59M10.64M11.52M10.07M16.97M18.02M
EBITDA -2.56M-2.29M-1.80M-2.57M-2.37M-2.17M-1.76M-1.68M-4.58M-5.27M-7.54M-0.37M-3.13M-1.03M
Interest ExpensesInt Expense -0.01M0.02M0.08M0.02M